http://hl7.org/fhir/uv/ebm/Citation/264329
type: Citation
node role: treeRoot
id:
  v: 264329
meta:
  version id:
    v: 15
  last updated:
    v: 2025-10-13T12:34:35.118Z
  profile:
    v: http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation
    l: journal-article-citation
language:
  v: en
text:
  status:
    v: extensions
  div:
    v: Generated Narrative: Citation 264329 version: 15; Last updated: 2025-10-13 12:34:35+0000 Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: Citation 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. identifier: FEvIR Object Identifier/264329, https://pubmed.ncbi.nlm.nih.gov/37024129, <a href="http://terminology.hl7.org/7.0.1/NamingSystem-uri.html" title="As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt #xD;#xA;#xD;#xA;This oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: #xD;#xA;#xD;#xA;Note that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.#xD;#xA;#xD;#xA;This OID may also be used in CD.codeSystem.">Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.11 version: 1.0.0-ballot3 title: 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. status: Active date: 2026-01-08 11:24:31+0000 author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: HL7 International / Clinical Decision Support contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medli…
contained: Practitioner
  id:
    v: contributor0
  identifier:
    type:
      text:
        v: ORCID
    system:
      v: https://orcid.org/
      l: orcid.org
    value:
      v: 0000-0003-4299-5889
  name:
    family:
      v: Shi
    given:
      v: Qingyang
contained: Practitioner
  id:
    v: contributor1
  name:
    family:
      v: Nong
    given:
      v: Kailei
contained: Practitioner
  id:
    v: contributor2
  name:
    family:
      v: Vandvik
    given:
      v: Per Olav
contained: Practitioner
  id:
    v: contributor3
  name:
    family:
      v: Guyatt
    given:
      v: Gordon H
contained: Practitioner
  id:
    v: contributor4
  name:
    family:
      v: Schnell
    given:
      v: Oliver
contained: Practitioner
  id:
    v: contributor5
  name:
    family:
      v: Rydén
    given:
      v: Lars
contained: Practitioner
  id:
    v: contributor6
  name:
    family:
      v: Marx
    given:
      v: Nikolaus
contained: Practitioner
  id:
    v: contributor7
  name:
    family:
      v: Brosius
    given:
      v: Frank C
contained: Practitioner
  id:
    v: contributor8
  name:
    family:
      v: Mustafa
    given:
      v: Reem A
contained: Practitioner
  id:
    v: contributor9
  name:
    family:
      v: Agarwal
    given:
      v: Arnav
contained: Practitioner
  id:
    v: contributor10
  name:
    family:
      v: Zou
    given:
      v: Xinyu
contained: Practitioner
  id:
    v: contributor11
  name:
    family:
      v: Mao
    given:
      v: Yunhe
contained: Practitioner
  id:
    v: contributor12
  name:
    family:
      v: Asadollahifar
    given:
      v: Aminreza
contained: Practitioner
  id:
    v: contributor13
  name:
    family:
      v: Chowdhury
    given:
      v: Saifur Rahman
contained: Practitioner
  id:
    v: contributor14
  name:
    family:
      v: Zhai
    given:
      v: Chunjuan
contained: Practitioner
  id:
    v: contributor15
  name:
    family:
      v: Gupta
    given:
      v: Sana
contained: Practitioner
  id:
    v: contributor16
  name:
    family:
      v: Gao
    given:
      v: Ya
contained: Practitioner
  id:
    v: contributor17
  name:
    family:
      v: Lima
    given:
      v: João Pedro
contained: Practitioner
  id:
    v: contributor18
  name:
    family:
      v: Numata
    given:
      v: Kenji
contained: Practitioner
  id:
    v: contributor19
  name:
    family:
      v: Qiao
    given:
      v: Zhi
contained: Practitioner
  id:
    v: contributor20
  name:
    family:
      v: Fan
    given:
      v: Qinlin
contained: Practitioner
  id:
    v: contributor21
  name:
    family:
      v: Yang
contained: ArtifactAssessment

v: PRN

v: Provider number

v: Qinbo

Practitioner
id:
  v: contributor22
name:
  family:
    v: Jin
  given:
    v: Yinghui

Practitioner
id:
  v: contributor23
name:
  family:
    v: Ge
  given:
    v: Long

Practitioner
id:
  v: contributor24
name:
  family:
    v: Yang
  given:
    v: Qiuyu

Practitioner
id:
  v: contributor25
name:
  family:
    v: Zhu
  given:
    v: Hongfei

Practitioner
id:
  v: contributor26
name:
  family:
    v: Yang
  given:
    v: Fan

Practitioner
id:
  v: contributor27
name:
  family:
    v: Chen
  given:
    v: Zhe

Practitioner
id:
  v: contributor28
name:
  family:
    v: Lu
  given:
    v: Xi

Practitioner
id:
  v: contributor29
name:
  family:
    v: He
  given:
    v: Siyu

Practitioner
id:
  v: contributor30
name:
  family:
    v: Chen
  given:
    v: Xiangyang

Practitioner
id:
  v: contributor31
name:
  family:
    v: Lyu
  given:
    v: Xiafei

Practitioner
id:
  v: contributor32
name:
  family:
    v: An
  given:
    v: Xingxing

Practitioner
id:
  v: contributor33
name:
  family:
    v: Chen
  given:
    v: Yaolong

Practitioner
id:
  v: contributor34
name:
  family:
    v: Hao
  given:
    v: Qiukui

Practitioner
id:
  v: contributor35
name:
  family:
    v: Standl
  given:
    v: Eberhard

Practitioner
id:
  v: contributor36
name:
  family:
    v: Siemieniuk
  given:
    v: Reed

Practitioner
id:
  v: contributor37
name:
  family:
    v: Agoritsas
  given:
    v: Thomas

Practitioner
id:
  v: contributor38
name:
  family:
    v: Tian
  given:
    v: Haoming

Practitioner
id:
  v: contributor39
identifier:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/v2-0203
        l: v2-0203
      code:
        v: PRN
      display:
        v: Provider number
    text:
      v: ORCID
  system:
    v: https://orcid.org/
    l: orcid.org
  value:
    v: 0000-0003-0060-0287
name:
  family:
    v: Li
  given:
    v: Sheyu

ArtifactAssessment
id:
  v: meshHeading0
artifact: Reference
  l: #
  reference:
    v: #
  type:
    v: Citation
    l: Citation
content:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: mesh-heading
      display:
        v: MeSH heading
    text:
      v: components (if present) include qualifier codings
  classifier:
    coding: D000328
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D000328
      display:
        v: Adult
      user selected:
        v: false
  free to share:
    v: true
  component:
    type:
      text:
        v: qualifier
    classifier:
      text:
        v: is not a major topic
content:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: mesh-heading
      display:
        v: MeSH heading
    text:
      v: components (if present) include qualifier codings
  classifier:
    coding: D006801
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D006801
      display:
        v: Humans
      user selected:
        v: false
  free to share:
    v: true
  component:
    type:
      text:
        v: qualifier
    classifier:
      text:
        v: is not a major topic
content:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: mesh-heading
      display:
        v: MeSH heading
    text:
      v: components (if present) include qualifier codings
  classifier:
    coding: D003924
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D003924
      display:
        v: Diabetes Mellitus, Type 2
      user selected:
        v: false
  free to share:
    v: true
  component:
    type:
      text:
        v: qualifier
    classifier:
      text:
        v: is Major topic
  component:
    type:
      text:
        v: qualifier
    classifier:
      coding: Q000188
content:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: mesh-heading
      display:
        v: MeSH heading
    text:
      v: components (if present) include qualifier codings
  classifier:
    coding: http://id.nlm.nih.gov/mesh/D000077203
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D000077203
      display:
        v: Sodium-Glucose Transporter 2 Inhibitors
      user selected:
        v: false
  free to share:
    v: true
  component:
    type:
      text:
        v: qualifier
    classifier:
      text:
        v: is Major topic
  component:
    type:
      text:
        v: qualifier
    classifier:
      coding: Q000009
content:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: mesh-heading
      display:
        v: MeSH heading
    text:
      v: components (if present) include qualifier codings
  classifier:
    coding: D000451
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: D000451
      display:
        v: Mineralocorticoid Receptor Antagonists
      user selected:
        v: false
  free to share:
    v: true
  component:
    type:
      text:
        v: qualifier
    classifier:
      text:
        v: is not a major topic
  component:
    type:
      text:
        v: qualifier
    classifier:
      coding: Q000009
content:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
        l: cited-artifact-classification-type
      code:
        v: mesh-heading
      display:
        v: MeSH heading
    text:
      v: components (if present) include qualifier codings
  classifier:
    coding: http://id.nlm.nih.gov/mesh/D000071076
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh

v: Q000188

v: drug therapy

v: is Major topic

system:
  v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
  l: Thesaurus.owl
code:
  v: C49487
display:
  v: No

v: Q000009

v: adverse effects

v: is Major topic

system:
  v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
  l: Thesaurus.owl
code:
  v: C49487
display:
  v: No

v: Q000009

v: adverse effects

v: is Major topic

system:
  v: http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl
  l: Thesaurus.owl
code:
  v: C49487
display:
  v: No

v: D000071076

v: Network Meta-Analysis

v: false

v: true

type:
  text:
    v: qualifier
classifier:
  text:
    v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: http://id.nlm.nih.gov/mesh/D000067757
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000067757
    display:
      v: Glucagon-Like Peptide-1 Receptor
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic
component:
  type:
    text:
      v: qualifier
  classifier:
    coding: Q000627
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000627
      display:
        v: therapeutic use
  component:
    type:
      text:
        v: is Major topic

v: C49487

v: No

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D011788
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D011788
    display:
      v: Quality of Life
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D007676
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D007676
    display:
      v: Kidney Failure, Chronic
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is Major topic

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D006333
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D006333
    display:
      v: Heart Failure
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is Major topic
component:
  type:
    text:
      v: qualifier
  classifier:
    coding: Q000188
      system:
        v: https://www.nlm.nih.gov/mesh
        l: mesh
      code:
        v: Q000188
      display:
        v: drug therapy
  component:
    type:
      text:
        v: is Major topic

v: C49487

v: No

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
  text:
    v: components (if present) include qualifier codings
classifier:
  coding: D016032
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016032
    display:
      v: Randomized Controlled Trials as Topic
    user selected:
      v: false
free to share:
  v: true
component:
  type:
    text:
      v: qualifier
  classifier:
    text:
      v: is not a major topic

url:
  v: http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status
  l: artifact-publication-status
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-status-type
      l: cited-artifact-status-type
    code:
      v: active
    display:
      v: Active

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/v2-0203
      l: v2-0203
    code:
      v: ACSN
    display:
      v: Accession ID
  text:
    v: FEvIR Object Identifier
system:
  v: https://fevir.net/FOI
  l: FOI
value:
  v: 264329
assigner:
  display:
    v: Computable Publishing LLC

system:
  v: https://pubmed.ncbi.nlm.nih.gov
  l: pubmed.ncbi.nlm.nih.gov
value:
  v: 37024129

system:
  v: urn:ietf:rfc:3986
  l: 3986
value:
  v: urn:oid:2.16.840.1.113883.4.642.40.44.15.11

v: 1.0.0-ballot3

v: 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.

v: active

v: 2026-01-08T11:24:31+00:00

name:
  v: Computable Publishing®: MEDLINE-to-FEvIR Converter

v: HL7 International / Clinical Decision Support

name:
  v: HL7 International / Clinical Decision Support
telecom:
  system:
    v: url
  value:
    v: http://www.hl7.org/Special/committees/dss

v: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

code:
  system:
    v: http://terminology.hl7.org/CodeSystem/citation-classification-type
    l: citation-classification-type
  code:
    v: fevir-platform-use
  display:
    v: FEvIR Platform Use
value: CodeableConcept
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: medline-base
    display:
      v: Medline Base
    user selected:
      v: false

coding:
  system:
    v: http://unstats.un.org/unsd/methods/m49/m49.htm
    l: m49.htm
  code:
    v: 001
  display:
    v: World

v: 2023-04-10

v: 2025-03-14

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: citation-source
    display:
      v: Citation Source
classifier:
  text:
    v: MEDLINE

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-classification-type
      l: citation-classification-type
    code:
      v: medline-owner
    display:
      v: MEDLINE Citation Owner
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value
      l: owner value
    code:
      v: NLM
    display:
      v: National Library of Medicine, Index Section
    user selected:
      v: false

coding:
  system:
    v: http://hl7.org/fhir/citation-status-type
    l: citation-status-type
  code:
    v: medline-medline
  display:
    v: Medline Citation Status of Medline

coding:
  system:
    v: http://hl7.org/fhir/citation-status-type
    l: citation-status-type
  code:
    v: pubmed-publication-status-epublish
  display:
    v: PubMed PublicationStatus of epublish

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-medline
    display:
      v: PubMed Pubstatus of Medline
period:
  end:
    v: 2023-04-10T06:42:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-entrez
    display:
      v: PubMed Pubstatus of Entrez
period:
  end:
    v: 2023-04-06T20:43:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-pubmed
    display:
      v: PubMed Pubstatus of Pubmed
period:
  end:
    v: 2023-04-07T06:00:00.000Z

activity:
  coding:
    system:
      v: http://hl7.org/fhir/citation-status-type
      l: citation-status-type
    code:
      v: pubmed-pubstatus-pmc-release
    display:
      v: PubMed Pubstatus of PMC release
period:
  end:
    v: 2023-04-06

identifier:
  system:
    v: https://pubmed.ncbi.nlm.nih.gov
    l: pubmed.ncbi.nlm.nih.gov
  value:
    v: 37024129
identifier:
  system:
    v: https://www.ncbi.nlm.nih.gov/pmc/
    l: pmc
  value:
    v: PMC10077111
identifier:
  system:
    v: https://doi.org
    l: doi.org
  value:
    v: 10.1136/bmj-2022-074068
title:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/title-type
        l: title-type
      code:
        v: primary
      display:
        v: Primary title
  text:
    v: Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
abstract:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type
        l: cited-artifact-abstract-type
      code:
        v: primary-human-use
      display:
        v: Primary human use
  text:
    v: **OBJECTIVE:** To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options. <AbstractText Label="DESIGN">Systematic review and network meta-analysis. <AbstractText Label="DATA SOURCES">Ovid Medline, Embase, and Cochrane Central up to 14 October 2022. <AbstractText Label="ELIGIBILITY CRITERIA FOR SELECTING STUDIES">Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following the GRADE (grading of recommendations, assessment, development and evaluation) approach. **RESULTS:** The analysis identified 816 trials with 471 038 patients, together evaluating 13 different drug classes; all subsequent estimates refer to the comparison with standard treatments. Sodium glucose cotransporter-2 (SGLT-2) inhibitors (odds ratio 0.88, 95% confidence interval 0.83 to 0.94; high certainty) and GLP-1 receptor agonists (0.88, 0.82 to 0.93; high certainty) reduce all cause death; non-steroidal mineralocorticoid receptor antagonists, so far tested only with finerenone in patients with chronic kidney disease, probably reduce mortality (0.89, 0.79 to 1.00; moderate certainty); other drugs may not. The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocardial infarction, admission to hospital for heart failure, and end stage kidney disease. Finerenone probably reduces admissions to hospital for heart failure and e…
  copyright:
    v: © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Gregg EW, Jakicic JM, Blackburn G, et al. Look AHEAD Research Group . Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016;4:913-21. 10.1016/S2213-8587(16)30162-0.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Palmer SC, Tendal B, Mustafa RA, et al. . Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021;372:m4573. 10.1136/bmj.m4573.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Li S, Vandvik PO, Lytvyn L, et al. . SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ 2021;373:n1091. 10.1136/bmj.n1091.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Bakris GL, Agarwal R, Anker SD, et al. FIDELIO-DKD Investigators . Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-29. 10.1056/NEJMoa2025845.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Pitt B, Filippatos G, Agarwal R, et al. FIGARO-DKD Investigators . Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021;385:2252-63. 10.1056/NEJMoa2110956.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Rosenstock J, Wysham C, Frías JP, et al. . Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021;398:143-55. 10.1016/S0140-6736(21)01324-6.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Frías JP, Davies MJ, Rosenstock J, et al. SURPASS-2 Investigators . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503-15. 10.1056/NEJMoa2107519.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Ludvik B, Giorgino F, Jódar E, et al. . Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 2021;398:583-98. 10.1016/S0140-6736(21)01443-4.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Del Prato S, Kahn SE, Pavo I, et al. SURPASS-4 Investigators . Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021;398:1811-24. 10.1016/S0140-6736(21)02188-7.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Dahl D, Onishi Y, Norwood P, et al. . Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA 2022;327:534-45. 10.1001/jama.2022.0078.
relates to:
  type:
    v: cites
  classifier:
    coding:
      system:
        v: http://hl7.org/fhir/citation-artifact-classifier
        l: citation-artifact-classifier
      code:
        v: D016428
      display:
        v: Journal Article
  citation:
    v: Rydén L, Standl E. After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk. N Engl J Med 2022;387:1136-8. 10.1056/NEJMe2210531.
relates to:
  type:
    v: cites

coding:
  system:
    v: http://hl7.org/fhir/citation-artifact-classifier
    l: citation-artifact-classifier
  code:
    v: D016428
  display:
    v: Journal Article

v: Nathan DM, Lachin JM, Balasubramanyam A, et al. GRADE Study Research Group . Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med 2022;387:1063-74. 10.1056/NEJMoa2200433.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Nathan DM, Lachin JM, Bebu I, et al. GRADE Study Research Group . Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med 2022;387:1075-88. 10.1056/NEJMoa2200436.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Marx N, Ryden L, Brosius F, et al. . Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. Diabetes Res Clin Pract 2021;177:108870. 10.1016/j.diabres.2021.108870.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Page MJ, McKenzie JE, Bossuyt PM, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. 10.1136/bmj.n71.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Hutton B, Salanti G, Caldwell DM, et al. . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84. 10.7326/M14-2385.

type:
  v: cites
citation:
  v: Guyatt G, Busse J. Methods Commentary: Risk of Bias in Randomized Trials 1. DistillerSR. 2011. https://www.distillersr.com/resources/methodological-resources/risk-of-bias-commentary.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Levin A, Agarwal R, Herrington WG, et al. participant authors of the International Society of Nephrology’s 1st International Consensus Meeting on Defining Kidney Failure in Clinical Trials . International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int 2020;98:849-59. 10.1016/j.kint.2020.07.013.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Rücker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods 2012;3:312-24. 10.1002/jrsm.1058.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Shi Q, Wang Y, Hao Q, et al. . Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2022;399:259-69. 10.1016/S0140-6736(21)01640-8.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Bhaumik DK, Amatya A, Normand S-L, et al. . Meta-Analysis of Rare Binary Adverse Event Data. J Am Stat Assoc 2012;107:555-67. 10.1080/01621459.2012.664484.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3:98-110. 10.1002/jrsm.1044.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: König J, Krahn U, Binder H. Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons. Stat Med 2013;32:5414-29. 10.1002/sim.6001.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Wiksten A, Hawkins N, Piepho H-P, Gsteiger S. Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis. Value Health 2020;23:918-27. 10.1016/j.jval.2020.03.010.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Efthimiou O, Rücker G, Schwarzer G, Higgins JPT, Egger M, Salanti G. Network meta-analysis of rare events using the Mantel-Haenszel method. Stat Med 2019;38:2992-3012. 10.1002/sim.8158.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Schandelmaier S, Briel M, Varadhan R, et al. . Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ 2020;192:E901-6. 10.1503/cmaj.200077.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Balshem H, Helfand M, Schünemann HJ, et al. . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6. 10.1016/j.jclinepi.2010.07.015.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Davies AL, Papakonstantinou T, Nikolakopoulou A, Rücker G, Galla T. Network meta-analysis and random walks. Stat Med 2022;41:2091-114. 10.1002/sim.9346.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Puhan MA, Schünemann HJ, Murad MH, et al. GRADE Working Group . A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630. 10.1136/bmj.g5630.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. . GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. J Clin Epidemiol 2021;137:163-75. 10.1016/j.jclinepi.2021.03.026.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. . GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. J Clin Epidemiol 2022;150:216-24. 10.1016/j.jclinepi.2022.07.014

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Brignardello-Petersen R, Florez ID, Izcovich A, et al. GRADE working group . GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ 2020;371:m3900. 10.1136/bmj.m3900.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Phillips MR, Sadeghirad B, Busse JW, et al. . Development and design validation of a novel network meta-analysis presentation tool for multiple outcomes: a qualitative descriptive study. BMJ Open 2022;12:e056400. 10.1136/bmjopen-2021-056400.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Buchan TA, Malik A, Chan C, et al. . Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses. Heart 2021;107:1962-73. 10.1136/heartjnl-2021-319243.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Wright AK, Carr MJ, Kontopantelis E, et al. . Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Diabetes Care 2022;45:909-18. 10.2337/dc21-1113.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Rossing P, Anker SD, Filippatos G, et al. FIDELIO-DKD and FIGARO-DKD Investigators . Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care 2022;45:2991-8. 10.2337/dc22-0294.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Sato N, Ajioka M, Yamada T, et al. ARTS-HF Japan study group . A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. Circ J 2016;80:1113-22. 10.1253/circj.CJ-16-0122.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Ruilope LM, Pitt B, Anker SD, et al. . Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant 2023;38:372-83.

type:
  v: cites
citation:
  v: Bayer. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction ≥ 40% (LVEF ≥ 40%). Clinicaltrials.gov. 2022. https://clinicaltrials.gov/ct2/show/NCT04435626.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Hundemer GL, Sood MM. Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management. Pharmacol Res 2021;172:105835. 10.1016/j.phrs.2021.105835.

type:
  v: cites
citation:
  v: Eli Lilly and Company. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT). clinicaltrials.gov 2022. https://clinicaltrials.gov/ct2/show/NCT04255433.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:642-53. 10.1038/s41574-020-0399-8.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Liu J, Li L, Li S, et al. . Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2020;22:1619-27. 10.1111/dom.14075.

type:
  v: cites
classifier:
  coding:
    system:
      v: http://hl7.org/fhir/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
citation:
  v: Lin C, Zhu X, Cai X, et al. . SGLT2 inhibitors and lower limb complications: an updated meta-analysis. Cardiovasc Diabetol 2021;20:91. 10.1186/s12933-021-01276-9.

type:
  v: comment-in
classifier:
  coding: D016420
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016420
    display:
      v: Comment
    user selected:
      v: false
citation:
  v: Acad Emerg Med. 2024 Aug;31(8):832-834. doi: 10.1111/acem.14922.

published in:
  type:
    coding:
      system:
        v: http://terminology.hl7.org/CodeSystem/published-in-type
        l: published-in-type
      code:
        v: D020492
      display:
        v: Periodical
  identifier:
    type:
      text:
        v: Electronic ISSN Type
    system:
      v: https://portal.issn.org
      l: portal.issn.org
    value:
      v: 1756-1833
  identifier:
    type:
      text:
        v: ISOAbbreviation
    system:
      v: https://www.issn.org/services/online-services/access-to-the-ltwa/
      l: access-to-the-ltwa
    value:
      v: BMJ
  identifier:
    type:
      text:
        v: ISSN Linking
    system:
      v: https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/
      l: the-issn-l-for-publications-on-multiple-media
    value:
      v: 0959-8138
  identifier:
    type:
      text:
        v: Medline Title Abbreviation
    system:
      v: https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html
      l: contructitleabbre.html
    value:
      v: BMJ
  identifier:
    type:
      text:
        v: NLM Unique ID
    system:
      v: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
      l: https://locatorplus.gov/cgi-bin/Pwebrecon.cgi
    value:
      v: 8900488
  title:
    v: BMJ (Clinical research ed.)
  publisher location:
    v: England
cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet
    display:
      v: Internet
volume:
  v: 381
article date:
  v: 2023-04-06
page string:
  v: e074068

v: Electronic

v: Electronic

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

v: XX

v: Organization identifier

cited medium:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-medium
      l: cited-medium
    code:
      v: internet-without-issue
    display:
      v: Internet without issue
article date:
  v: 2023-04-06

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: abstract
    display:
      v: Abstract
url:
  v: https://pubmed.ncbi.nlm.nih.gov/37024129/
  l: https://pubmed.ncbi.nlm.nih.gov/37024129/

classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/artifact-url-classifier
      l: artifact-url-classifier
    code:
      v: doi-based
    display:
      v: DOI Based
url:
  v: https://doi.org/10.1136/bmj-2022-074068
  l: bmj-2022-074068

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publishing-model
    display:
      v: Publishing Model
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: Electronic
    display:
      v: Electronic
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: chemical
    display:
      v: Chemical
    user selected:
      v: false
classifier:
  coding: http://id.nlm.nih.gov/mesh/D000077203
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000077203
    display:
      v: Sodium-Glucose Transporter 2 Inhibitors
    user selected:
      v: false
classifier:
  coding: D000451
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000451
    display:
      v: Mineralocorticoid Receptor Antagonists
    user selected:
      v: false
classifier:
  coding: http://id.nlm.nih.gov/mesh/D000067757
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000067757
    display:
      v: Glucagon-Like Peptide-1 Receptor
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: mesh-heading
    display:
      v: MeSH heading
artifact assessment:
  l: meshHeading0
  reference:
    v: #meshHeading0
  type:
    v: ArtifactAssessment
    l: ArtifactAssessment

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: publication-type
    display:
      v: Publication type
classifier:
  coding: D017418
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D017418
    display:
      v: Meta-Analysis
    user selected:
      v: false
classifier:
  coding: http://id.nlm.nih.gov/mesh/D000078182
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D000078182
    display:
      v: Systematic Review
    user selected:
      v: false
classifier:
  coding: D016428
    system:
      v: https://www.nlm.nih.gov/mesh
      l: mesh
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: knowledge-artifact-type
    display:
      v: Knowledge Artifact Type
    user selected:
      v: false
classifier:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/citation-artifact-classifier
      l: citation-artifact-classifier
    code:
      v: D016428
    display:
      v: Journal Article
    user selected:
      v: false
artifact assessment:
  display:
    v: Classifier added by Computable Publishing LLC

type:
  coding:
    system:
      v: http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type
      l: cited-artifact-classification-type
    code:
      v: citation-subset
    display:
      v: Citation subset
    user selected:
      v: false
classifier:
  coding:
    system:
      v: https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset
      l: citationsubset
    code:
      v: IM
    display:
      v: IM
    user selected:
      v: false

complete:
  v: true
entry:
  contributor:
    l: contributor0
    reference:
      v: #contributor0
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Shi Q
  forename initials:
    v: Q
  affiliation:
    display:
      v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.
entry:
  contributor:
    l: contributor1
    reference:
      v: #contributor1
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Nong K
  forename initials:
    v: K
  affiliation:
    display:
      v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.
entry:
  contributor:
    l: contributor2
    reference:
      v: #contributor2
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Vandvik PO
  forename initials:
    v: PO
  affiliation:
    display:
      v: Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway.
entry:
  contributor:
    l: contributor3
    reference:
      v: #contributor3
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Guyatt GH
  forename initials:
    v: GH
  affiliation:
    display:
      v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.
entry:
  contributor:
    l: contributor4
    reference:
      v: #contributor4
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Schnell O
  forename initials:
    v: O
  affiliation:
    display:
      v: Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany.
entry:
  contributor:
    l: contributor5
    reference:
      v: #contributor5
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Rydén L
  forename initials:
    v: L
  affiliation:
    display:
      v: Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden.
entry:
  contributor:
    l: contributor6
    reference:
      v: #contributor6
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Marx N
  forename initials:
    v: N
  affiliation:
    display:
      v: Clinic for Cardiology, Angiology, and Intensive Care Medicine, RWTH Aachen University, University Hospital Aachen, Aachen, Germany.
entry:
  contributor:
    l: contributor7
    reference:
      v: #contributor7
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Brosius FC
  forename initials:
    v: FC
  affiliation:
    display:
      v: Division of Nephrology, University of Arizona College of Medicine Tucson, Tucson, AZ, USA.
entry:
  contributor:
    l: contributor8
    reference:
      v: #contributor8
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Mustafa RA
  forename initials:
    v: RA
  affiliation:
    display:
      v: Department of Internal Medicine, Division of Nephrology and Hypertension, University of Kansas, Kansas City, MI, USA.
entry:
  contributor:
    l: contributor9
    reference:
      v: #contributor9
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Agarwal A
  forename initials:
    v: A
  affiliation:
    display:
      v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.
  affiliation:
    display:
      v: Department of Medicine, McMaster University, Hamilton, ON, Canada.
entry:
  contributor:
    l: contributor10
    reference:
      v: #contributor10
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Zou X
  forename initials:
    v: X
  affiliation:
    display:
      v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.
entry:
  contributor:
    l: contributor11
    reference:
      v: #contributor11
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Mao Y
  forename initials:
    v: Y
  affiliation:
    display:
      v: Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China.
entry:
  contributor:
    l: contributor12
    reference:
      v: #contributor12
    type:
      v: Practitioner
      l: Practitioner
    display:
      v: Asadollahifar A
  forename initials:
    v: A
  affiliation:
    display:
      v: Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

contributor:
  l: contributor13
  reference:
    v: #contributor13
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Chowdhury SR
forename initials:
  v: SR
affiliation:
  display:
    v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.

contributor:
  l: contributor14
  reference:
    v: #contributor14
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Zhai C
forename initials:
  v: C
affiliation:
  display:
    v: Department of Cardiology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China.

contributor:
  l: contributor15
  reference:
    v: #contributor15
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Gupta S
forename initials:
  v: S
affiliation:
  display:
    v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.

contributor:
  l: contributor16
  reference:
    v: #contributor16
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Gao Y
forename initials:
  v: Y
affiliation:
  display:
    v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.
affiliation:
  display:
    v: Evidence-Based Medicine Centre, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.

contributor:
  l: contributor17
  reference:
    v: #contributor17
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Lima JP
forename initials:
  v: JP
affiliation:
  display:
    v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.

contributor:
  l: contributor18
  reference:
    v: #contributor18
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Numata K
forename initials:
  v: K
affiliation:
  display:
    v: Department of Emergency Medicine, St Marianna University School of Medicine, Kawasaki, Japan.

contributor:
  l: contributor19
  reference:
    v: #contributor19
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Qiao Z
forename initials:
  v: Z
affiliation:
  display:
    v: West China School of Medicine, Sichuan University, Chengdu, China.

contributor:
  l: contributor20
  reference:
    v: #contributor20
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Fan Q
forename initials:
  v: Q
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor21
  reference:
    v: #contributor21
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Yang Q
forename initials:
  v: Q
affiliation:
  display:
    v: Department of Nephrology, National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor22
  reference:
    v: #contributor22
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Jin Y
forename initials:
  v: Y
affiliation:
  display:
    v: Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.

contributor:
  l: contributor23
  reference:
    v: #contributor23
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Ge L
forename initials:
  v: L
affiliation:
  display:
    v: Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China.

contributor:
  l: contributor24
  reference:
    v: #contributor24
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Yang Q
forename initials:
  v: Q
affiliation:
  display:
    v: Evidence-Based Nursing Centre, School of Nursing, Lanzhou University, Lanzhou, China.

contributor:
  l: contributor25
  reference:
    v: #contributor25
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Zhu H
forename initials:
  v: H
affiliation:
  display:
    v: Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, China.

contributor:
  l: contributor26
  reference:
    v: #contributor26
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Yang F
forename initials:
  v: F
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, Chengdu Fifth People's Hospital, Chengdu, China.

contributor:
  l: contributor27
  reference:
    v: #contributor27
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Chen Z
forename initials:
  v: Z
affiliation:
  display:
    v: Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

contributor:
  l: contributor28
  reference:
    v: #contributor28
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Lu X
forename initials:
  v: X
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor29
  reference:
    v: #contributor29
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: He S
forename initials:
  v: S
affiliation:
  display:
    v: Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor30
  reference:
    v: #contributor30
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Chen X
forename initials:
  v: X
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, First People's Hospital of Shuangliu District, Chengdu, China.

contributor:
  l: contributor31
  reference:
    v: #contributor31
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Lyu X
forename initials:
  v: X
affiliation:
  display:
    v: Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor32
  reference:
    v: #contributor32
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: An X
forename initials:
  v: X
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor33
  reference:
    v: #contributor33
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Chen Y
forename initials:
  v: Y
affiliation:
  display:
    v: Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China.

contributor:
  l: contributor34
  reference:
    v: #contributor34
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Hao Q
forename initials:
  v: Q
affiliation:
  display:
    v: School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada.

contributor:
  l: contributor35
  reference:
    v: #contributor35
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Standl E
forename initials:
  v: E
affiliation:
  display:
    v: Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany.

contributor:
  l: contributor36
  reference:
    v: #contributor36
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Siemieniuk R
forename initials:
  v: R
affiliation:
  display:
    v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.

contributor:
  l: contributor37
  reference:
    v: #contributor37
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Agoritsas T
forename initials:
  v: T
affiliation:
  display:
    v: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.
affiliation:
  display:
    v: Division of General Internal Medicine, Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland.

contributor:
  l: contributor38
  reference:
    v: #contributor38
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Tian H
forename initials:
  v: H
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

contributor:
  l: contributor39
  reference:
    v: #contributor39
  type:
    v: Practitioner
    l: Practitioner
  display:
    v: Li S
forename initials:
  v: S
affiliation:
  display:
    v: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China lisheyu@gmail.com.